Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CARA |
---|---|---|
09:32 ET | 7345 | 0.61 |
09:34 ET | 263 | 0.6186 |
09:36 ET | 235 | 0.6114 |
09:48 ET | 600 | 0.6149 |
09:52 ET | 100 | 0.6148 |
09:57 ET | 1100 | 0.6205 |
09:59 ET | 500 | 0.6229 |
10:03 ET | 1350 | 0.62015 |
10:08 ET | 477 | 0.6148 |
10:12 ET | 100 | 0.6202 |
10:14 ET | 244 | 0.6148 |
10:15 ET | 867 | 0.6224 |
10:19 ET | 300 | 0.6296 |
10:21 ET | 1400 | 0.614801 |
10:26 ET | 492 | 0.63 |
10:32 ET | 300 | 0.6201 |
10:35 ET | 120 | 0.625049 |
10:37 ET | 250 | 0.6299 |
10:39 ET | 4990 | 0.63 |
10:44 ET | 415 | 0.639005 |
10:46 ET | 400 | 0.63005 |
10:48 ET | 950 | 0.6399 |
10:50 ET | 100 | 0.6201 |
10:53 ET | 100 | 0.621 |
10:55 ET | 100 | 0.621 |
11:00 ET | 100 | 0.638 |
11:02 ET | 1585 | 0.625 |
11:06 ET | 1100 | 0.6299 |
11:09 ET | 564 | 0.625 |
11:11 ET | 1300 | 0.629251 |
11:13 ET | 100 | 0.625 |
11:20 ET | 7495 | 0.6313 |
11:22 ET | 170 | 0.63783 |
11:24 ET | 924 | 0.6321 |
11:31 ET | 100 | 0.632 |
11:44 ET | 2350 | 0.6389 |
11:45 ET | 5243 | 0.6322 |
11:49 ET | 500 | 0.6321 |
11:54 ET | 165 | 0.6431 |
11:56 ET | 640 | 0.64 |
12:02 ET | 1170 | 0.6401 |
12:07 ET | 500 | 0.6436 |
12:12 ET | 306 | 0.6427 |
12:14 ET | 5173 | 0.65 |
12:16 ET | 136 | 0.6555 |
12:23 ET | 300 | 0.6518 |
12:27 ET | 311 | 0.655 |
12:32 ET | 12609 | 0.6558 |
12:34 ET | 500 | 0.6516 |
12:38 ET | 100 | 0.648 |
12:41 ET | 300 | 0.648 |
12:45 ET | 200 | 0.6436 |
12:48 ET | 100 | 0.6436 |
12:52 ET | 630 | 0.6403 |
12:54 ET | 21879 | 0.6599 |
12:56 ET | 1284 | 0.6599 |
12:57 ET | 358 | 0.64825 |
12:59 ET | 630 | 0.6549 |
01:01 ET | 100 | 0.6513 |
01:03 ET | 317 | 0.64797 |
01:14 ET | 1839 | 0.654815 |
01:15 ET | 3249 | 0.64 |
01:17 ET | 172 | 0.632 |
01:19 ET | 7680 | 0.6321 |
01:21 ET | 216 | 0.632 |
01:28 ET | 1950 | 0.6358 |
01:39 ET | 100 | 0.6321 |
01:46 ET | 200 | 0.6453 |
01:50 ET | 2699 | 0.6441 |
01:55 ET | 1000 | 0.6406 |
01:57 ET | 2001 | 0.6321 |
02:00 ET | 1458 | 0.64 |
02:04 ET | 300 | 0.64 |
02:08 ET | 5200 | 0.632 |
02:09 ET | 200 | 0.632 |
02:11 ET | 100 | 0.632 |
02:13 ET | 100 | 0.632 |
02:15 ET | 100 | 0.632 |
02:18 ET | 1050 | 0.6388 |
02:20 ET | 100 | 0.632 |
02:24 ET | 200 | 0.632 |
02:26 ET | 399 | 0.632 |
02:27 ET | 200 | 0.632 |
02:29 ET | 5163 | 0.64 |
02:31 ET | 419 | 0.6431 |
02:33 ET | 800 | 0.6459 |
02:36 ET | 2830 | 0.65 |
02:40 ET | 200 | 0.65 |
02:42 ET | 100 | 0.645 |
02:45 ET | 20903 | 0.64665 |
02:47 ET | 1100 | 0.64 |
02:49 ET | 700 | 0.6495 |
02:51 ET | 100 | 0.641 |
02:54 ET | 847 | 0.6425 |
02:56 ET | 345 | 0.6419 |
02:58 ET | 800 | 0.64 |
03:00 ET | 100 | 0.64 |
03:02 ET | 1901 | 0.64 |
03:03 ET | 300 | 0.64 |
03:07 ET | 3900 | 0.6406 |
03:09 ET | 100 | 0.64 |
03:12 ET | 100 | 0.64 |
03:18 ET | 1678 | 0.645 |
03:21 ET | 100 | 0.64 |
03:23 ET | 749 | 0.64 |
03:27 ET | 100 | 0.64 |
03:30 ET | 2575 | 0.64 |
03:32 ET | 300 | 0.6438 |
03:36 ET | 200 | 0.64 |
03:38 ET | 1200 | 0.64 |
03:39 ET | 200 | 0.6425 |
03:41 ET | 1489 | 0.64 |
03:43 ET | 100 | 0.6455 |
03:48 ET | 975 | 0.6401 |
03:52 ET | 905 | 0.64 |
03:54 ET | 8931 | 0.64 |
03:56 ET | 1922 | 0.6429 |
03:57 ET | 1957 | 0.64295 |
03:59 ET | 54257 | 0.6494 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cara Therapeutics Inc | 32.7M | -0.3x | --- |
ImmuCell Corp | 34.1M | -8.4x | --- |
Aadi Bioscience Inc | 42.6M | -0.7x | --- |
SQZ Biotechnologies Co | 1.3M | 0.0x | --- |
Viaderma Inc | 8.3M | 0.0x | --- |
Turnstone Biologics Corp | 60.8M | -0.7x | --- |
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.7M |
---|---|
Revenue (TTM) | $16.9M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-2.26 |
Book Value | $1.05 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 1.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -729.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.